Supplementary Figure 3

Sep 01, 2014

10 likes | 71 Views

A. Signal A= SE1 Photo No. = 1291. 3µm*. B. EHT = 10.00kV Zone Mag = 5.01KX WD = 14mm. Supplementary Figure 3.

signal
eht 10
supplementary figure 3
01kx wd 14mm
00kv zone mag 5

blake

Download Presentation

Supplementary Figure 3

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

A Signal A= SE1 Photo No. = 1291 3µm* B EHT = 10.00kV Zone Mag = 5.01KX WD = 14mm Supplementary Figure 3

Supplementary Figure 3

Supplementary Figure 3. A. B. Dry weight of grain in a panicle (g/panicle) .

86 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3. #. . . 2.0. #. . #. . 1.5. #. Luciferase Activity. 1.0. 0.5. 0.0. Vehicle IL-1α SC-514 [50 μ M]. +--. --+. -+-. -++. +--. --+. -+-. -++. +--. --+. -+-. -++. +--. --+. -+-. -++.

82 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3. MDSC subsets. Lymphocyte subsets. Treg subsets.

84 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3. A. B.

52 views • 1 slides

Supplementary Figure 3 6

A. B. C. Supplementary Figure 3 6.

70 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3. Cell Lines. TOV112D. TOV21G. HEY. HES. T80. IE. 102 kDa. 76 kDa. Transferrin receptor (CD71). Ferritin (FTH). 17 kDa. 12 kDa. 76 kDa. p66 Shc. 52 kDa. p52 Shc. p46 Shc. 17 kDa. LC3-I. LC3-II. 12 kDa. 17 kDa. LC3-I. 12 kDa. LC3-II. 120 kDa.

100 views • 1 slides

Supplementary Figure 3

control. control. ZVAD. ZVAD. JNK Inhibitor. JNK Inhibitor. ZVAD+JNK Inhibitor. ZVAD+JNK Inhibitor. 120. 100. 80. % Control. 60. 40. 20. 0. 0. 6.25. 12.5. 25. 50. Cerulenin μ M. U266. 120. 100. 80. % Control. 60. 40. 20. 0. 0. 6.25. 12.5. 25. 50.

99 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3. Telomeric aUPD. A. Total aUPD. B. MRC. MRC. MRC. MRC. MRC. GIST. GIST. GIST. GIST. GIST. EWS. EWS. EWS. EWS. EWS. aRMS. aRMS. aRMS. aRMS. aRMS. Leiomyosarcoma. Leiomyosarcoma. Leiomyosarcoma. Leiomyosarcoma. Leiomyosarcoma. D. C.

116 views • 1 slides

Supplementary figure 3

1. 2. 3. 4. 5. 6. M. M. 1. 2. Probe: Unc5b. 7 kb. 28 s RNA. Supplementary figure 3. a. Specificity of the Unc5b splicing morpholino .

77 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3. a. b. BMDM. BMDM. c. d. BMDM. BMDM.

83 views • 1 slides

Supplementary Figure 3

Ctl sip300. p300. E2F1. Actin. Cisp (24h). Supplementary Figure 3. A. B. 25. NT. Cisp (24h). 20. Apoptosis (%). 15. 10. 5. 0. Ctl. sip300. Neutralization of p300 prevents E2F1 accumulation and apoptosis in response to cisplatin.

114 views • 1 slides

Supplementary figure 3

Supplementary figure 3. A. B. C.

55 views • 1 slides

Supplementary Figure 3

4. A. dilutions vs OD450-NPPA. dilutions vs OD450-PP1A. dilutions vs OD450-PP2A. 3. 2. OD450nm. 1. 0. 2. 4. 8. 16. 32. 64. 128. 256. 512. 1024. 2048. Dilution factor (number x 1000). B. Competitors. NPP. PP1. PP2. Primary antibody. Coating antigens. NPP. 152. 302.

183 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3.

86 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3. MDA-MB-231. MDA-MB-231 HM.

62 views • 1 slides

Supplementary Figure 3

t. t. OFF. ON. OFF. OFF. ON. ON. a1. a2. a3. a5. a6. a4. ON. OFF. b1. Firing rate (Hz). Seconds. Supplementary Figure 3. a. Dark background. (used in the fMRI experiments). Firing rate (Hz). Firing rate (Hz). Seconds. Seconds. Seconds. b. Isoluminant transition. OFF.

92 views • 2 slides

Supplementary Figure 3

b. a. d. c. Supplementary Figure 3.

68 views • 1 slides

Supplementary Figure 3

CNV Sensitivity Analysis Run 1. CNV Sensitivity Analysis Run 2. H460 (100%). H460 (100%). cMYC amplification. EGFR loss. H460 (50%). H460 (50%). H460 (25%). H460 (25%). H460 (12.5%). H460 (12.5%). H460 (6.25%). H460 (6.25%). Supplementary Figure 3.

79 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3. PELP1 Tg. Con. A. Phos MAPK. Con. PELP1 Tg. B. Phos AKT. Figure S3. Representative IHC images showing the status of phos -MAPK ( A )and phos -AKT ( B )in the mammary glands of 6-month-old control and MMTV-rtTA-TetO-PELP1 bitransgenic mice.

210 views • 1 slides

Supplementary Figure 3

HCT116. HCT116-TP53KO. NT. 5FU. Ox. NT. 5FU. Ox. 5. 2. 4. LC3. 3. IC50 5FU (µM). 1. IC50 Oxaliplatin (µM). 2. 1. GAPDH. 0. 0. HCT116. HCT116 TP53KO. HCT116. HCT116 TP53KO. 6. 5. 4. 7. HCT116. IC50 5FU (µM). 3. 6. HCT116. 0.4. 2. 5. 4. 1. 0.3. IC50 5FU (µM).

130 views • 1 slides

Supplementary Figure 3

Supplementary Figure 3. a. iPrEC. Untreated. Untreated. Doxo (0,75 µM). DTX (10 nM). % ROS. % Apoptosis (Ann V+/PI- cells). b. iPrEC. -. -. -. -. -. -. +. +. +. +. +. +. c. NAC. NAC. EV. USP2a MUT. USP2a WT. Untreated. Untreated. Doxo (0,75 µM). Doxo

109 views • 1 slides

Supplementary Figure 3

Fold of difference. Fold of difference. FEMALES. A. BM. PB. *. *. *. *. B. Fold of difference. Fold of difference. MALES. BM. *. PB. *. *. Supplementary Figure 3. *p<0,05.

82 views • 1 slides

More Related